The development of nanoparticles for drug delivery is a fast-moving and high-potential research area within the pharmaceutical industry. A leading company in the field has now chosen Inhalation Research Services for a contract research project that is exploring the development of inhalable nanoporous particles for drug delivery.

The company wishes to evaluate how test particles dissolve in the lung in vivo, and how quickly they move into the bloodstream. To do so, they have chosen to use ISAB’s intratracheal in vivo exposure module. This delivers aerosol directly to the lungs of an individual test rodent, bypassing its nose, whilst carefully monitoring aerosol concentration and individual breathing patterns. The method delivers voluminous data with exceptionally high precision.

ISAB CEO Manoush Masarrat: "We are pleased that this company, a clear leader in its field, has chosen our technology because of its proven precision and reliability. When finalized, we certainly aim to expand our cooperation and carry out more projects further down the line."

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on February 17, 2021.